Autolus Therapeutics (AUTL) vs Contineum Therapeutics (CTNM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Autolus Therapeutics (AUTL) has outperformed Contineum Therapeutics (CTNM) over the past year, gaining 21.5% versus a gain of 11.8%. Contineum Therapeutics is the larger company by market cap ($472.0 million vs $464.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AUTL | CTNM |
|---|---|---|
| Share price | $1.75 | $12.55 |
| Market cap | $464.45M | $471.96M |
| 1-day change | -3.59% | -1.45% |
| YTD return | -9.05% | +11.37% |
| 1-year return | +21.48% | +11.76% |
| 5-year return | -70.52% | — |
| EPS (TTM) | $-1.06 | $-1.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.58 | $17.79 |
| 52-week low | $1.18 | $8.60 |
| Distance from 52-week high | -32.36% | -29.46% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +400.29% | +78.80% |
| Average volume | 2.10M | 502.82K |
| Shares outstanding | 266.16M | 32.96M |
| Employees | 752 | 51 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Autolus Therapeutics
AUTL stock →Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 752 employees
About Contineum Therapeutics
CTNM stock →Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 51 employees
AUTL vs CTNM FAQ
Which is bigger, Autolus Therapeutics or Contineum Therapeutics?
Contineum Therapeutics (CTNM) is larger, with a market capitalization of $471.96M compared with $464.45M for Autolus Therapeutics (AUTL).
Which stock has performed better over the past year, AUTL or CTNM?
AUTL returned +21.48% over the past 12 months, compared with +11.76% for CTNM (price return, excluding dividends). Past performance does not predict future results.
Are Autolus Therapeutics and Contineum Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Autolus Therapeutics and Biotechnology: Pharmaceutical Preparations for Contineum Therapeutics.